AQST News and Press, Aquestive Therapeutics Inc. From 01/28/21

New hire helps lead Aquestive’s continued focus on its epinephrine program Provides update on Libervant™ (diazepam) Buccal Film WARREN, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused o...

Mitsubishi Tanabe Pharma America and Aquestive Therapeutics (AQST) announce a licensing and supply deal for the U.S. rights to commercialize EXSERVAN (riluzole), an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis ((ALS)).Mitsubishi will...

Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment PR Newswire JERSEY CITY, N.J. and WARREN, N.J. , Jan. 21, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. ...

Aquestive Therapeutics (AQST) provides business update:The company resubmitted a revised weight-based dosing regimen along with modeling and simulations for its seizure treatment Libervant in December 2020. Expects to resubmit the marketing application to the FDA during th...

Resubmitted revised dosing regimen for Libervant to FDA in December 2020, as committed Multiple clinical trials demonstrate that AQST-108 can consistently deliver epinephrine WARREN, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a p...

Aquestive Therapeutics are back from the brink, with key advancements in Libervant resubmission and longevity in shareholder value creation. The company entered into a royalty agreement for KYNMOBI, which will drive long-tailed asset returns for the creation of value for shareholders....

Aquestive Therapeutics ([[AQST]] +2.2%) has announced that John Maxwell, Senior Vice President, Chief Financial Officer of the Company, intents to resign.Ernie Toth, most recently with EHE Health as Chief Financial Officer, will assume the role of CFO on an interim basis upon Mr. Maxwell...

WARREN, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that John Maxwell...

WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the manageme...

WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today receipt of the fi...